The global biologics CDMO for mAb sector is entering a strong growth phase as pharmaceutical and biotechnology companies increasingly outsource monoclonal antibody development and manufacturing. It was valued at USD 20.84 billion in 2025 and is expected to reach USD 23.11 billion in 2026. By 2035, it is projected to reach USD 58.64 billion, expanding at a CAGR of 10.9% from 2026 to 2035.
Biologics CDMOs provide specialized services covering cell line development, process development, GMP manufacturing, analytical testing, fill-finish operations, and commercial production.
Key Trends
One major trend is the growth of end-to-end services. Pharmaceutical companies increasingly prefer integrated partners covering development, manufacturing, testing, and commercialization. This model can reduce complexity.
Expansion of high-capacity manufacturing facilities is another important trend. Rising demand for monoclonal antibodies and biologics is encouraging CDMOs to invest in large-scale facilities.
Flexible manufacturing platforms are also gaining attention. Modular facilities, single-use technologies, and multi-product systems allow CDMOs to support diverse projects.
Digital manufacturing and automation are transforming biologics production. AI-assisted process monitoring, advanced analytics, digital twins, and automated systems can improve process control, reduce errors, and optimize workflows.
Segment Insights
GMP manufacturing led the service type segment with a 41% share in 2025. Fill-finish services are expected to grow rapidly as injectable biologics expand.
Conventional monoclonal antibodies accounted for 63% of the molecule type segment in 2025, while bispecific antibodies are expected to expand rapidly because of growing clinical pipelines and greater manufacturing complexity.
CHO cells dominated the expression system segment with an 81% share, supported by their established role in therapeutic antibody production and productivity.
Commercial-scale manufacturing held the largest share at 54% in 2025. Clinical-scale manufacturing is expected to expand at a CAGR of 11.8%, supported by clinical development activity.
Regional Outlook
North America accounted for 43% in 2025, supported by biologics research, advanced infrastructure, healthcare investment, and CDMO capabilities. Asia Pacific accounted for 21% and is expected to grow fastest, driven by cost competitiveness, biotechnology expansion, government support, and outsourcing.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/7019
Future Outlook
The future will be shaped by bispecific antibodies, antibody-drug conjugates, single-use technologies, continuous bioprocessing, automation, artificial intelligence, and flexible manufacturing. CDMOs that strengthen end-to-end capabilities, advanced technology platforms, regulatory expertise, quality systems, and global manufacturing networks are likely to benefit from rising outsourcing demand. Continued capacity investment and next-generation biologics should support long-term growth.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium